| James B Rice Iii, MD | |
|
3800 S National Ave, Springfield, MO 65807-5209 | |
| (417) 875-3000 | |
| (417) 875-3295 |
| Full Name | James B Rice Iii |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 27 Years |
| Location | 3800 S National Ave, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417991894 | NPI | - | NPPES |
| 178516 | Other | BLUE CROSS/BLUE SHIELD | |
| 208742007 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 2003009741 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cox Medical Centers | Springfield, MO | Hospital |
| Texas County Memorial Hospital | Houston, MO | Hospital |
| Cox Monett Hospital | Monett, MO | Hospital |
| Cox Medical Center Branson | Branson, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lester E Cox Medical Centers | 1254248917 | 262 |
| Texas County Memorial Hospital | 9436041696 | 29 |
News Archive
Skipping IV clot-busters and using mechanical clot removal alone for strokes may be just as good as the combination of both treatments, with less risk of brain bleeding, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
Drug resistant bacteria are fast becoming one of the big worries of the 21 century. Now researchers at the University of Copenhagen have discovered a previously unknown weakness; an "Achilles heel", of bacteria. Their discovery, a crucial step in bacteria's energy metabolism, may be the first step in developing an entirely novel form of antibiotics
A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.
› Verified 3 days ago
| Entity Name | Texas County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790740363 PECOS PAC ID: 9436041696 Enrollment ID: O20040401000307 |
News Archive
Skipping IV clot-busters and using mechanical clot removal alone for strokes may be just as good as the combination of both treatments, with less risk of brain bleeding, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
Drug resistant bacteria are fast becoming one of the big worries of the 21 century. Now researchers at the University of Copenhagen have discovered a previously unknown weakness; an "Achilles heel", of bacteria. Their discovery, a crucial step in bacteria's energy metabolism, may be the first step in developing an entirely novel form of antibiotics
A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.
› Verified 3 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538334396 PECOS PAC ID: 1254248917 Enrollment ID: O20050624000293 |
News Archive
Skipping IV clot-busters and using mechanical clot removal alone for strokes may be just as good as the combination of both treatments, with less risk of brain bleeding, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
Drug resistant bacteria are fast becoming one of the big worries of the 21 century. Now researchers at the University of Copenhagen have discovered a previously unknown weakness; an "Achilles heel", of bacteria. Their discovery, a crucial step in bacteria's energy metabolism, may be the first step in developing an entirely novel form of antibiotics
A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.
› Verified 3 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750036703 PECOS PAC ID: 1254248917 Enrollment ID: O20220509000988 |
News Archive
Skipping IV clot-busters and using mechanical clot removal alone for strokes may be just as good as the combination of both treatments, with less risk of brain bleeding, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
Drug resistant bacteria are fast becoming one of the big worries of the 21 century. Now researchers at the University of Copenhagen have discovered a previously unknown weakness; an "Achilles heel", of bacteria. Their discovery, a crucial step in bacteria's energy metabolism, may be the first step in developing an entirely novel form of antibiotics
A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James B Rice Iii, MD Po Box 9007, Springfield, MO 65808-9007 Ph: (417) 875-3000 | James B Rice Iii, MD 3800 S National Ave, Springfield, MO 65807-5209 Ph: (417) 875-3000 |
News Archive
Skipping IV clot-busters and using mechanical clot removal alone for strokes may be just as good as the combination of both treatments, with less risk of brain bleeding, according to late breaking science presented today at the American Stroke Association's International Stroke Conference 2020.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
Drug resistant bacteria are fast becoming one of the big worries of the 21 century. Now researchers at the University of Copenhagen have discovered a previously unknown weakness; an "Achilles heel", of bacteria. Their discovery, a crucial step in bacteria's energy metabolism, may be the first step in developing an entirely novel form of antibiotics
A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.
› Verified 3 days ago
Dr. Mark H. Grimm, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3231 S National Ave, Springfield, MO 65807 Phone: 417-888-5696 Fax: 417-888-6711 | |
Dr. Sridevi Durga, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3800 S National Ave, Suite 400, Springfield, MO 65807 Phone: 417-875-2633 Fax: 417-875-3295 | |
Bradley D Wiley, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1001 E Primrose St, Springfield, MO 65807 Phone: 417-875-3000 Fax: 417-875-3051 | |
Walter S. Trombold, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6044 S Overlook Trl, Springfield, MO 65810 Phone: 417-771-5778 | |
Dr. Timi A Akins, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4814 S Montrose Pl, Springfield, MO 65810 Phone: 202-779-1247 | |
Ghulam Jeelani Siddiqui, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2115 S Fremont Ave, Suite 3300, Springfield, MO 65804 Phone: 417-820-5200 Fax: 417-820-5220 | |
Danny R Penick, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3801 S National Ave, Springfield, MO 65807 Phone: 417-269-0000 |